On this page
MODY2 (GCK diabetes)
MODY2 is a type of maturity-onset diabetes of the young (MODY) that typically results in lifelong, mild high blood glucose. It is caused by genetic changes in the GCK gene and is often inherited in an autosomal dominant manner.
Overview
MODY2, or GCK diabetes, is a specific type of diabetes mellitus that differs from the more common Type 1 and Type 2 diabetes. It is one of several forms of maturity-onset diabetes of the young (MODY), which are monogenic conditions, meaning they are caused by a change in a single gene [PMID:33675037]. In MODY2, the body's 'glucose sensor' doesn't work as effectively, leading to a slightly higher 'set point' for blood sugar levels, typically from birth.
This condition accounts for approximately 1-2% of all diabetes cases. Unlike Type 1 diabetes, which involves an autoimmune attack on insulin-producing cells, or Type 2 diabetes, often linked to insulin resistance and lifestyle factors, MODY2 is primarily a disorder of glucose sensing. Individuals with MODY2 often have moderately elevated fasting blood glucose levels that remain relatively stable throughout their lives, without the progressive increase seen in Type 2 diabetes [PMID:35035073].
Recognising MODY2 is important because its management differs significantly from other types of diabetes. Misdiagnosis can lead to inappropriate treatment, such as unnecessary insulin therapy, which can result in hypoglycaemia (low blood sugar). Correct diagnosis allows for tailored management, which often involves dietary advice and monitoring rather than medication.
Symptoms & clinical features
Individuals with MODY2 typically do not experience the classic symptoms of high blood sugar (hyperglycaemia) that are common in other forms of diabetes, such as excessive thirst, frequent urination, or unexplained weight loss. This is because their blood glucose levels are usually only mildly elevated. The condition is often discovered incidentally during routine blood tests, such as those performed during pregnancy or for other health checks, where consistently raised fasting blood glucose is observed [PMID:33675037].
Blood glucose levels in MODY2 usually range between 5.5 and 8 mmol/L. While these levels are higher than typical, they are usually not high enough to cause noticeable symptoms or significant long-term complications associated with severe diabetes. Glycated haemoglobin (HbA1c) levels, which indicate average blood sugar over several months, are also typically only mildly elevated.
In some cases, MODY2 may be identified during pregnancy screening if gestational diabetes is suspected. However, it's important to differentiate MODY2 from gestational diabetes, as the management approaches are different. For most individuals, the condition is mild and stable, often not requiring medication beyond careful monitoring and lifestyle adjustments.
Video: Genetics 101
Affected organs
MODY2 primarily affects the pancreas and liver, as these organs are key players in blood glucose regulation. The genetic change in the GCK gene impacts the function of glucokinase, an enzyme that acts as a 'glucose sensor' in these tissues.
In the beta cells of the pancreas, glucokinase is crucial for sensing blood glucose levels and triggering the release of insulin. When glucokinase function is altered in MODY2, the pancreatic beta cells become less sensitive to glucose, meaning they require a higher blood glucose level to release insulin. This leads to slightly higher baseline blood glucose levels.
Similarly, in the liver, glucokinase plays a role in glucose uptake and storage. A dysfunctional glucokinase can lead to the liver also operating at a higher glucose set point. While these changes impact glucose metabolism in these vital organs, the effects are generally mild, and the organs typically function well otherwise without significant damage directly attributable to MODY2.
Risks & severity
MODY2 is generally considered a mild form of diabetes with a favourable prognosis. The elevated blood glucose levels typically remain stable throughout an individual's life and do not usually progress to the severe hyperglycaemia seen in other forms of diabetes. This means that serious long-term complications often associated with diabetes, such as kidney disease, nerve damage (neuropathy), or eye problems (retinopathy), are rare in individuals with MODY2 and are often no more common than in the general population [PMID:35035073].
While MODY2 is a lifelong condition, its severity is low, and many individuals manage it effectively with dietary advice and regular monitoring. During pregnancy, careful monitoring is recommended, as women with MODY2 may have slightly increased risks for larger babies (macrosomia) due to the baby's exposure to higher glucose levels. However, most pregnancies in women with MODY2 are uncomplicated, and the condition often does not require insulin during gestation.
Genetic causes
MODY2 is caused by pathogenic variants in the GCK gene, which provides instructions for making an enzyme called glucokinase. This enzyme plays a crucial role in regulating blood glucose levels. Glucokinase acts as a 'glucose sensor' in several tissues, including the beta cells of the pancreas and the liver. Its primary function is to trigger the initial step of glucose metabolism when blood glucose levels rise.
In the pancreatic beta cells, glucokinase is responsible for detecting increased glucose and signalling the release of insulin. In the liver, it helps the liver take up glucose for storage. When there is a pathogenic variant in the GCK gene, the glucokinase enzyme does not function as efficiently. This means that the pancreatic beta cells become less sensitive to glucose and require a higher blood glucose concentration to release insulin [PMID:35035073].
Consequently, individuals with GCK variants have a slightly higher 'set point' for blood glucose, meaning their bodies maintain blood sugar at a mildly elevated level, typically between 5.5 and 8 mmol/L. This persistent, but usually mild, hyperglycaemia is the hallmark of MODY2.
- GCK glucokinaseThe GCK gene provides instructions for producing glucokinase, an enzyme vital for glucose metabolism and the regulation of insulin secretion, with implications for various forms of diabetes.
Inheritance pattern
MODY2 is inherited in an autosomal dominant pattern. This means that an individual only needs to inherit one copy of the altered GCK gene from either parent to develop the condition. If one parent has MODY2, there is a 50% chance with each pregnancy that their child will also inherit the genetic variant and develop the condition, regardless of the child's sex.
Autosomal dominant inheritance implies that the condition can appear in every generation of an affected family. Family history can therefore be a significant clue for diagnosis. Individuals with MODY2 can pass the condition on to their children. Genetic counselling can provide more detailed information about inheritance patterns and risks for family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
The diagnosis of MODY2 is typically suspected when an individual has persistently elevated fasting blood glucose levels (usually between 5.5-8 mmol/L) or a mildly raised HbA1c, particularly without the classic symptoms of diabetes or features of insulin resistance [PMID:33675037]. A family history of mild diabetes, often diagnosed incidentally, can also raise suspicion for MODY2.
Confirmation of MODY2 requires genetic testing to identify a pathogenic variant in the GCK gene. This testing is usually arranged by a clinical geneticist or an endocrinologist. In the UK, genetic testing for MODY is available through the NHS Genomic Medicine Service (GMS). Referral to clinical genetics services is typically made by a GP or specialist. The relevant NHS National Genomic Test Directory R-code for monogenic diabetes (including MODY2) is R189. This test confirms the diagnosis, which is crucial for appropriate management and to distinguish it from other types of diabetes.
Management & lifestyle
Management for MODY2 is generally conservative due to its mild nature and low risk of complications. The primary goal is usually to confirm the diagnosis to avoid unnecessary medication and provide appropriate lifestyle advice. For most individuals, regular monitoring of blood glucose and HbA1c levels is sufficient.
Dietary advice, focusing on a healthy, balanced diet, is often recommended. Unlike Type 1 or Type 2 diabetes, individuals with MODY2 rarely require oral hypoglycaemic agents or insulin therapy. Initiating such treatments unnecessarily can increase the risk of hypoglycaemia, which is generally not a concern in MODY2. There may be specific considerations during pregnancy, where closer monitoring is advised to minimise potential risks for the baby, though insulin is still often not required.
Individuals diagnosed with MODY2 are typically managed within the NHS by their GP, often in conjunction with an endocrinologist. Genetic counsellors play a vital role in explaining the condition, its inheritance, and the implications for family members. They can also help families navigate genetic testing and provide support.
UK care pathway
In the UK, the care pathway for individuals suspected of having MODY2 typically begins with a referral to a specialist, such as an endocrinologist or a clinical geneticist, through their GP. Once MODY2 is suspected, genetic testing is often recommended to confirm the diagnosis. This testing is provided by the NHS Genomic Medicine Service (GMS) under the National Genomic Test Directory, using R-code R189 for monogenic diabetes.
Upon diagnosis, individuals and their families will often have access to genetic counselling services. Genetic counsellors provide detailed information about the condition, its inheritance pattern, implications for family planning, and can help to coordinate testing for other family members. Long-term management is typically overseen by a GP with specialist input as needed, focusing on monitoring and lifestyle guidance.
Frequently asked questions
What is the difference between MODY2 and Type 2 diabetes?
MODY2 is a genetic condition present from birth, leading to mildly raised blood sugar due to a 'glucose sensor' issue. Type 2 diabetes usually develops later in life, often linked to lifestyle, and involves the body becoming resistant to insulin or not producing enough.
Will my children inherit MODY2?
MODY2 is inherited in an autosomal dominant pattern. If you have MODY2, each of your children has a 50% chance of inheriting the genetic change and therefore having the condition themselves.
Do I need to take medication for MODY2?
Most people with MODY2 do not need medication. The condition typically results in mild, stable blood glucose levels that can be managed with lifestyle advice and monitoring, without needing drugs or insulin.
What are the long-term health risks of MODY2?
MODY2 is generally a mild condition with a very low risk of long-term diabetes complications like kidney disease, nerve damage, or eye problems. These are typically no more common than in the general population.
How is MODY2 diagnosed in the UK?
Diagnosis of MODY2 in the UK usually involves genetic testing for changes in the GCK gene, often after a specialist suspects the condition based on persistently mildly raised blood glucose. This testing is available through the NHS Genomic Medicine Service.